Sep 9 2009
Cochlear, the global leader in implantable hearing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved the Nucleus((R) )5 System for adults and children with severe-to-profound hearing loss. Working with leading surgeons and audiologists worldwide, Cochlear has developed the most advanced technology including a smaller and thinner device with an unparalleled capability to deliver superior hearing performance and better user comfort. The Nucleus 5 System is the only one of its kind on the market today that offers the smallest, most water resistant sound processor, the thinnest titanium cochlear implant, two-way remote assistant, SmartSound((TM)) 2 technology and AutoPhone((TM)) capability.
Cochlear implants have the ability to restore hearing for individuals who are severely hard of hearing or profoundly deaf and who receive limited to no benefit from hearing aids. The new Nucleus 5 System is the most advanced cochlear implant system on the market for all ages*, which includes powerful features designed to restore hearing in deaf children so that they have the greatest potential to develop the spoken language skills necessary for school. Adults will benefit from advanced features that deliver the best listening options for phone use, communication in noisy environments and music enjoyment.
"Cochlear has reached a significant milestone with the introduction of the Nucleus 5 System. We have built upon our industry-leading hearing performance and reliability record with new, unique features designed to give users greater flexibility and help them hear better in difficult situations. We celebrate this milestone with the dedicated clinicians who have helped us positively impact the lives of so many people," said Chris Smith, President of Cochlear Americas.
Vitamin D supplements during pregnancy strengthen children's bones